Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer

详细信息    查看全文

• 作者：Lishuang Wang ; Yuanfu Mao ; Guiqin Du ; Chunbo He ; Shiyu Han
• 关键词：Epithelial ovarian carcinoma (EOC) ; JARID1B ; Prognosis ; Chemotherapy resistance
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：36
• 期：4
• 页码：2465-2472
• 全文大小：582 KB
• 参考文献：1.Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. 2005. CA Cancer J Clin. 2005;55:10-0.View Article PubMed
  2.Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H, et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011;129(3):629-5.View Article PubMed
  3.Yin M, Li C, Li X, Lou G, Miao B, Liu X, et al. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011;104(1):29-6.View Article PubMed
  4.Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377:127-8.View Article PubMed Central PubMed
  5.Christensen J, Agger K, Cloos P, Pasini D, Rose S, Sennels L, et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 2007;128:1063-6.View Article PubMed
  6.Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25:801-2.View Article PubMed
  7.Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH, et al. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell. 2007;128:1077-8.View Article PubMed
  8.Barrett A, Madsen B, Copier J, Lu PJ, Cooper L, Scibetta AG, et al. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer. 2002;101:581-.View Article PubMed
  9.Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S, et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically upregulated in breast cancer. J Biol Chem. 1999;274:15633-5.View Article PubMed
  10.Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583-4.View Article PubMed Central PubMed
  11.Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B (high) cells. Cancer Cell. 2013;23(6):811-5.View Article PubMed
  12.Robert J, Morgan Jr, Ronald D, Miller CR, Leath CA 3rd. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. National Comprehensive Cancer Network Clin Pract Guidel Oncol. 2009;2
  13.Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762-7.View Article PubMed
  14.Kano Y, Konno M, Ohta K, Haraguchi N, Nishikawa S, Kagawa Y, et al. Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth. Mol Clin Oncol. 2013;1(4):753-.PubMed Central PubMed
  15.Zhang L, Sokolowski N, Atmadibrata B, Liu T. Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein. Oncol Rep. 2014;31(4):1935-.PubMed
  16.Radberger P, Radberger A, Bykov VJ, Seregard S, Economou MA. JARID1B protein expression and prognostic implications in uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53(8):4442-.View Article PubMed
  17.Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A. 2007;104(49):19226-1.View Article PubMed Central PubMed
  
• 作者单位：Lishuang Wang (1)
  Yuanfu Mao (2)
  Guiqin Du (3)
  Chunbo He (1)
  Shiyu Han (1)
  
  1. Department of Gynecology and Obstetrics, The Fourth Affiliated Hospital of Harbin Medical University, Yiyuan Road 37, Nangang District, Harbin, 150001, China
  2. Department of Clinical Medicine, Harbin Medical University, Xuefu Road 194, Nangang District, Harbin, China
  3. Department of Clinical Laboratory, The Second Affiliated Hospital of Harbin Medical University, Xuefu Road 19, Nangang District, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

JARID1B, a histone demethylase, has been reported to be highly expressed in various human cancers. In the present study, we investigated the association of JARID1B level with epithelial ovarian cancer (EOC) and prognosis of patients with EOC. We analyzed JARID1B expression in 20 normal ovaries, 20 benign ovarian tumor (BOT) samples, and 45 epithelial ovarian carcinoma specimens by quantitative PCR (qRT-PCR) and western blotting analyses. JARID1B was further examined in 120 EOC specimens from patients with different histological stages via immunohistochemistry. Possible correlations between JARID1B levels and prognosis as well as chemotherapy resistance of EOC patients were determined by univariate and multivariate analyses. JARID1B level was significantly increased in EOC, as compared to normal ovaries and BOT. Among 120 EOC cases examined, the 5-year progression-free survival (PFS) rates were 17 and 85?% in patients with high and low JARID1B expression, respectively (hazard ratio--7.85, 95?% confidence interval (CI) 6.31-0.51, P-lt;-.001). Similarly, the 5-year overall survival (OS) rates for patients with high and low JARID1B expression were 28 and 92?% respectively (hazard ratio--1.8, 95?% CI 5.92-1.81, P-lt;-.001). Positive correlation between JARID1B level and chemotherapy resistance was observed in patients with EOC (odds ratio (OR) 36.81, 95?% CI 4.84-80.11, P-lt;-.001). JARID1B could serve as an important biomarker for prognosis and chemotherapy resistance of EOC patients.